Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents

ESMO Guidelines Committee

doi:10.1016/j.annonc.2023.02.015

Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents

ESMO Guidelines Committee

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

20 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	557-563
Nombre de pages	7
journal	Annals of Oncology
Volume	34
Numéro de publication	6
Les DOIs	https://doi.org/10.1016/j.annonc.2023.02.015
état	Publié - 1 juin 2023

Accès au document

10.1016/j.annonc.2023.02.015

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{9fcdc0fb30d744cf96864bc8e55836f7,

title = "Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents",

keywords = "Clinical Practice Guideline, Lu-PSMA, abiraterone–prednisone, cabazitaxel, darolutamide, prostate cancer",

author = "{ESMO Guidelines Committee} and K. Fizazi and S. Gillessen",

note = "Funding Information: The authors thank C. Parker, E. Castro, A. Heidenreich, P. Ost, G. Procopio and B. Tombal, authors of the ESMO Clinical Practice Guideline on Prostate Cancer, 1 for their review of this eUpdate. Manuscript editing support was provided by Louise Green, Jennifer Lamarre and Claire Bramley (ESMO Guidelines staff) and Angela Corstorphine of Kstorfin Medical Communications Ltd (KMC); this support was funded by ESMO. Nathan Cherny, Chair of the ESMO-MCBS Working Group, Urani Dafni, ESMO-MCBS Working Group Member/Frontier Science Foundation Hellas, and Giota Zygoura of Frontier Science Foundation Hellas provided review and validation of the ESMO-MCBS scores. Nicola Latino (ESMO Scientific Affairs staff) provided coordination and support of the ESMO-MCBS scores and Angela Corstorphine and Sian-Marie Lucas of KMC provided medical writing and editing support in the preparation of the ESMO-MCBS table; this support was funded by ESMO . ",

year = "2023",

month = jun,

day = "1",

doi = "10.1016/j.annonc.2023.02.015",

language = "English",

volume = "34",

pages = "557--563",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "6",

}

TY - JOUR

T1 - Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents

AU - ESMO Guidelines Committee

AU - Fizazi, K.

AU - Gillessen, S.

N1 - Funding Information: The authors thank C. Parker, E. Castro, A. Heidenreich, P. Ost, G. Procopio and B. Tombal, authors of the ESMO Clinical Practice Guideline on Prostate Cancer, 1 for their review of this eUpdate. Manuscript editing support was provided by Louise Green, Jennifer Lamarre and Claire Bramley (ESMO Guidelines staff) and Angela Corstorphine of Kstorfin Medical Communications Ltd (KMC); this support was funded by ESMO. Nathan Cherny, Chair of the ESMO-MCBS Working Group, Urani Dafni, ESMO-MCBS Working Group Member/Frontier Science Foundation Hellas, and Giota Zygoura of Frontier Science Foundation Hellas provided review and validation of the ESMO-MCBS scores. Nicola Latino (ESMO Scientific Affairs staff) provided coordination and support of the ESMO-MCBS scores and Angela Corstorphine and Sian-Marie Lucas of KMC provided medical writing and editing support in the preparation of the ESMO-MCBS table; this support was funded by ESMO .

PY - 2023/6/1

Y1 - 2023/6/1

KW - Clinical Practice Guideline

KW - Lu-PSMA

KW - abiraterone–prednisone

KW - cabazitaxel

KW - darolutamide

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85161561624&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2023.02.015

DO - 10.1016/j.annonc.2023.02.015

M3 - Article

C2 - 36958590

AN - SCOPUS:85161561624

SN - 0923-7534

VL - 34

SP - 557

EP - 563

JO - Annals of Oncology

JF - Annals of Oncology

IS - 6

ER -